{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-018000","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.461009+00:00","generated_at":"2026-05-20T22:38:31.283723+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx Pharmaceuticals reports Q1 net loss of $5.5M, advances NDA filings and HOPE clinic acquisitions","bullets":["Net loss narrowed to $5.5M for Q1 2025 from $6.5M in Q1 2024; operating loss $3.8M vs $6.0M.","Cash & cash equivalents $5.5M at March 31, 2025; company expects sufficient runway through end of 2025.","NDA for NRX-100 (IV ketamine) filing on track for Q2 2025; FDA waived $4.3M filing fee; U.S. patent application filed.","HOPE Therapeutics signed $7.8M debt term sheet with Universal Capital and $2.5M strategic investment for clinic acquisitions; initial clinics have ~$15M pro-forma revenue.","NRX-101 NDA submission for suicidal bipolar depression on track for 2025; anticipates PDUFA before year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-018000","json":"https://secwatch.observer/filing/0001437749-25-018000.json","markdown":"https://secwatch.observer/filing/0001437749-25-018000.md","text":"https://secwatch.observer/filing/0001437749-25-018000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925018000/0001437749-25-018000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925018000/nrxp20250521_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:38:31.283723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}